logo

For the Inventor, By the Inventor

Geel, Belgium

Bart Vanderborght

This inventor holds 6 USPTO granted patents. Top assignee: Innogenetics N.v.. Active years: 1994-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bart Vanderborght. Retrieved from https://idiyas.com/inventor/bart-vanderborght

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 32(Granted Patents)


Company Filing History:

goldMedal6 out of 82 
 
Innogenetics N.v.
 patents

Years Active: 1994-2001

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6265200 - HIV-3 retrovirus and its use (2001-07-24),
2. 6013484 - HIV-3 retrovirus and its use (2000-01-11),
3. 5858647 - Methods for detecting antibodies against HIV-3 retrovirus �and its use! (1999-01-12),
4. 5795743 - HIV-3 retrovirus antigen compositions (1998-08-18),
5. 5567603 - HIV-3 retrovirus and its use (1996-10-22),
6. 5304466 - HIV-3 retrovirus and its use (1994-04-19),

Title: Bart Vanderborght: Innovator in Retroviral Research

Introduction

Bart Vanderborght, an accomplished inventor based in Geel, Belgium, has made significant contributions to the field of retroviral research. With a total of six patents to his name, Vanderborght focuses on innovative solutions for diagnosing and treating conditions caused by retroviruses, particularly HIV.

Latest Patents

Vanderborght's latest patents highlight his groundbreaking work on the HIV-3 retrovirus. This new variety, also known as HIV-1 subtype O, has been classified and samples are deposited in the European Collection of Animal Cell Cultures under V88060301. His research describes the virus and its various variants, further detailing antigens derived from the virus. Specifically, proteins p12, p16, p25, and glycoproteins gp41 and gp120 are noted for their utility in diagnosing AIDS-related complex (ARC) and AIDS caused by HIV-3. Additionally, his immunogenic compositions utilizing envelope glycoproteins of HIV-3, such as gp41 or gp120, aim to serve as potential vaccines.

Career Highlights

Vanderborght's career is marked by his dedicated work at Innogenetics N.V., where he continues to push the boundaries of scientific research in retroviruses. His innovative spirit and commitment to advancing healthcare have positioned him as a respected figure in his field.

Collaborations

Throughout his career, Vanderborght has collaborated with notable professionals, including Robert De Leys and Eric Saman. These partnerships have fostered an environment of innovation and shared knowledge, driving forward the development of effective diagnostic and therapeutic solutions.

Conclusion

Bart Vanderborght stands out as a pioneering inventor in the realm of retroviral research. His patents not only reflect his commitment to scientific advancement but also hold promise for improving the diagnosis and treatment of conditions caused by retroviruses like HIV. Through his work at Innogenetics N.V. and collaboration with esteemed colleagues, he continues to lead the way in innovative healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…